With regards to the screening for preeclampsia in the first trimester, the NICE guidelines rely on maternal characteristics and medical history for risk assessment, whereas the FMF algorithm incorporates additional biochemical markers (PLGF or PAPP-A) and ultrasound parameters (UtA-PI). The gene discussed is PAPPA; the disease is preeclampsia.